FINWIRES · TerminalLIVE
FINWIRES

StemRIM Finishes Enrollment in Phase 1/2 Redasemtide Study

By

StemRIM (TYO:4599) said it has completed patient enrollment in a Phase 1/2 investigator-initiated clinical trial of its regenerative medicine candidate redasemtide for ischemic cardiomyopathy, according to a Wednesday filing on the Tokyo Stock Exchange.

The trial, conducted at five institutions led by Osaka University Hospital, enrolled 14 patients undergoing coronary artery bypass grafting, with participants receiving redasemtide or a placebo over five days.

The primary objective is to evaluate the drug's safety and tolerability, while efficacy will be assessed through cardiac function tests conducted 52 weeks after administration.

StemRIM said the enrollment was lower than the initially planned 20 patients, but deemed sufficient to evaluate the primary endpoints based on the overall progress of the trial.

Related Articles

Asia

Shenzhen Huaqiang Industry Forecasts Up to 120% Surge in Q1 Profit

Shenzhen Huaqiang Industry (SHE:000062) forecasts an 80% to 120% rise in its net attributable profit to between 190 million yuan and 232.3 million yuan in the first quarter from 105.6 million yuan in the year-ago period, according to a Wednesday filing with the Shenzhen bourse.The electronic information products maker attributed the expected rise to an increase in revenue from its storage products, with shipments surging 250% year over year, the filing said.Shares decreased 2% during the midday break on Wednesday.

SHE:000062
Asia

Shanghai International Airport Logs Higher March Passenger Throughput

Shanghai International Airport (SHA:600009) reported higher passenger throughput at its two airports in March, according to a Wednesday filing with the Shanghai bourse.At the Pudong International Airport, passenger throughput rose 11% year over year to 7.4 million, while its cargo and mail throughput climbed 8.1% to 372,100 tons, and aircraft movements increased 4.7% to 47,395 flights.The Hongqiao International Airport saw a 6.1% year-on-year rise in passenger throughput to 4.4 million, while cargo and mail throughput inched up 0.3% to 35,700 tons, and aircraft movements increased 2.4% to 24,683 flights.

SHA:600009
Asia

Hengyi Petrochemical's Q1 Profit Skyrockets 3,774%

Hengyi Petrochemical's (SHE:000703) net profit attributable to shareholders in the first quarter skyrocketed 3,774% to 1.99 billion yuan from 51.5 million yuan a year earlier, according to a Shenzhen bourse filing on Wednesday.Earnings per share surged 2,600% year on year to 0.54 yuan from 0.02 yuan.The petrochemical producer's operating revenue rose 10% to 29.9 billion yuan from 27.2 billion yuan in the prior year.

SHE:000703